{
  "schema_version": "0.4",
  "ir_kind": "hl",
  "metadata": {
    "title": "Cortical organoid differentiation and treatment conditions",
    "source": {
      "type": "paper",
      "id": "s41586-021-03209-8.pdf"
    }
  },
  "resources": {
    "materials": [],
    "containers": [],
    "equipment": [],
    "samples": [],
    "data": []
  },
  "protocol": {
    "steps": [
      {
        "id": "s1",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "description": "At day 35, organoids from each line were split into three different conditions: 1) normal medium conditions for day 35 and beyond as described above (with vitamin A); 2) normal medium conditions for day 35 and beyond (with vitamin A) plus 100 Î¼M DEAB, an inhibitor of RA synthesis; or 3) normal medium conditions for day 35 and beyond as described above except using B27 without vitamin A."
        }
      },
      {
        "id": "s2",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "description": "DEAB treatment was ended after one week, and culture conditions remained otherwise the same until day 70."
        }
      },
      {
        "id": "s3",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "description": "At day 70, organoids were processed for scRNA-seq and fixed for immunohistochemistry."
        }
      }
    ],
    "start_step_id": "s1",
    "edges": [
      {
        "from": "s1",
        "to": "s2"
      },
      {
        "from": "s2",
        "to": "s3"
      }
    ],
    "detail_level": 0
  }
}